Nissan Demonstrates Autonomous-Drive Mobility Services Progress on Public Roads
YOKOHAMA, Japan–(BUSINESS WIRE)–Nissan has commenced demonstrations of a prototype vehicle equipped with its in-house-developed, autonomous drive technologies... Read more.
Other World Computing Introduces Intel Thunderbolt Share for the Thunderbolt Go Dock
Exciting New Application from Intel Enables Fast PC-to-PC Connectivity TAIPEI, Taiwan–(BUSINESS WIRE)–#Intel—Other World Computing – the leading... Read more.
New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse
‘Ultra-sensitive’ cancer blood test is highly accurate in identifying which breast cancer patients will relapse The ‘Personalis NeXT Personal® liquid biopsy’... Read more.
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in... Read more.
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than three years... Read more.
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
The results include data from three main study cohorts: In the non-squamous non-small cell lung cancer (NSCLC) cohort, an Objective Response Rate (ORR) for NSCLC... Read more.
Stronger Than Ever: Adani Portfolio Delivers Record Performance
45% EBITDA growth in FY24, EBITDA reaches USD 10 Bn Adani Portfolio EBITDA increased to USD 10 Bn, up by record 45% Y-o-Y 84% of EBITDA is through “Core Infrastructure”... Read more.
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progression-free survival (PFS) Median PFS... Read more.
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from... Read more.
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify... Read more.